Is MDAI or RXST more profitable?

RxSight has a net margin of -36.58% compared to Spectral AI's net margin of -85.58%. Spectral AI's return on equity of 0.00% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets Spectral AI -85.58% N/A -72.97% RxSight -36.58% -17.01% -15.12%

Does the media refer more to MDAI or RXST?

In the previous week, RxSight had 6 more articles in the media than Spectral AI. MarketBeat recorded 11 mentions for RxSight and 5 mentions for Spectral AI. Spectral AI's average media sentiment score of 0.82 beat RxSight's score of 0.30 indicating that Spectral AI is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spectral AI 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RxSight 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MDAI or SMTI?

In the previous week, Spectral AI had 3 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for Spectral AI and 2 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.45 beat Spectral AI's score of 0.82 indicating that Sanara MedTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spectral AI 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LUCD or MDAI more profitable?

Spectral AI has a net margin of -85.58% compared to Lucid Diagnostics' net margin of -876.72%. Company Net Margins Return on Equity Return on Assets Lucid Diagnostics -876.72% N/A -116.26% Spectral AI -85.58% N/A -72.97%

Does the media favor KRMD or MDAI?

In the previous week, Spectral AI had 2 more articles in the media than KORU Medical Systems. MarketBeat recorded 5 mentions for Spectral AI and 3 mentions for KORU Medical Systems. Spectral AI's average media sentiment score of 0.82 beat KORU Medical Systems' score of 0.62 indicating that Spectral AI is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KORU Medical Systems 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spectral AI 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Spectral AI (MDAI) Competitors

$1.68 +0.01 (+0.30%)

As of 10:24 AM Eastern

Compare

MDAI vs. RXST, SMTI, LUCD, KRMD, and STEX

Should you buy Spectral AI stock or one of its competitors? MarketBeat compares Spectral AI with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spectral AI include RxSight (RXST), Sanara MedTech (SMTI), Lucid Diagnostics (LUCD), KORU Medical Systems (KRMD), and Biosig Technologies (STEX). These companies are all part of the "medical equipment" industry.

How does Spectral AI compare to RxSight?

Spectral AI (NASDAQ:MDAI) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Spectral AI currently has a consensus target price of $4.00, indicating a potential upside of 137.39%. RxSight has a consensus target price of $8.89, indicating a potential upside of 79.76%. Given Spectral AI's stronger consensus rating and higher possible upside, research analysts plainly believe Spectral AI is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

RxSight has a net margin of -36.58% compared to Spectral AI's net margin of -85.58%. Spectral AI's return on equity of 0.00% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spectral AI	-85.58%	N/A	-72.97%
RxSight	-36.58%	-17.01%	-15.12%

Spectral AI has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market. Comparatively, RxSight has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

In the previous week, RxSight had 6 more articles in the media than Spectral AI. MarketBeat recorded 11 mentions for RxSight and 5 mentions for Spectral AI. Spectral AI's average media sentiment score of 0.82 beat RxSight's score of 0.30 indicating that Spectral AI is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spectral AI	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RxSight	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 13.7% of Spectral AI shares are owned by insiders. Comparatively, 10.1% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Spectral AI has higher earnings, but lower revenue than RxSight. RxSight is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$19.65M	2.73	-$7.57M	-$0.53	N/A
RxSight	$134.48M	1.52	-$38.94M	-$1.13	N/A

Summary

Spectral AI beats RxSight on 10 of the 16 factors compared between the two stocks.

How does Spectral AI compare to Sanara MedTech?

Spectral AI (NASDAQ:MDAI) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

67.1% of Spectral AI shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 13.7% of Spectral AI shares are held by company insiders. Comparatively, 42.0% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Spectral AI currently has a consensus target price of $4.00, indicating a potential upside of 137.39%. Sanara MedTech has a consensus target price of $34.00, indicating a potential upside of 40.99%. Given Spectral AI's higher probable upside, analysts plainly believe Spectral AI is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Sanara MedTech has a net margin of -31.23% compared to Spectral AI's net margin of -85.58%. Spectral AI's return on equity of 0.00% beat Sanara MedTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spectral AI	-85.58%	N/A	-72.97%
Sanara MedTech	-31.23%	-3.19%	-0.56%

In the previous week, Spectral AI had 3 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for Spectral AI and 2 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.45 beat Spectral AI's score of 0.82 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spectral AI	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spectral AI has higher earnings, but lower revenue than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$19.65M	2.73	-$7.57M	-$0.53	N/A
Sanara MedTech	$103.12M	2.14	-$37.56M	-$3.77	N/A

Spectral AI has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

Summary

Sanara MedTech beats Spectral AI on 9 of the 17 factors compared between the two stocks.

How does Spectral AI compare to Lucid Diagnostics?

Lucid Diagnostics (NASDAQ:LUCD) and Spectral AI (NASDAQ:MDAI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Lucid Diagnostics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Spectral AI has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

Spectral AI has higher revenue and earnings than Lucid Diagnostics. Spectral AI is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	42.08	-$58.01M	-$0.47	N/A
Spectral AI	$19.65M	2.73	-$7.57M	-$0.53	N/A

In the previous week, Spectral AI had 4 more articles in the media than Lucid Diagnostics. MarketBeat recorded 5 mentions for Spectral AI and 1 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.87 beat Spectral AI's score of 0.82 indicating that Lucid Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Lucid Diagnostics	Very Positive
Spectral AI	Positive

Lucid Diagnostics currently has a consensus target price of $4.19, suggesting a potential upside of 329.05%. Spectral AI has a consensus target price of $4.00, suggesting a potential upside of 137.39%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Lucid Diagnostics is more favorable than Spectral AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 67.1% of Spectral AI shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by company insiders. Comparatively, 13.7% of Spectral AI shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Spectral AI has a net margin of -85.58% compared to Lucid Diagnostics' net margin of -876.72%.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
Spectral AI	-85.58%	N/A	-72.97%

Summary

Lucid Diagnostics beats Spectral AI on 8 of the 15 factors compared between the two stocks.

How does Spectral AI compare to KORU Medical Systems?

KORU Medical Systems (NASDAQ:KRMD) and Spectral AI (NASDAQ:MDAI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

KORU Medical Systems has higher revenue and earnings than Spectral AI. KORU Medical Systems is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KORU Medical Systems	$41.13M	4.64	-$2.64M	-$0.05	N/A
Spectral AI	$19.65M	2.73	-$7.57M	-$0.53	N/A

58.6% of KORU Medical Systems shares are held by institutional investors. Comparatively, 67.1% of Spectral AI shares are held by institutional investors. 18.5% of KORU Medical Systems shares are held by insiders. Comparatively, 13.7% of Spectral AI shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

KORU Medical Systems currently has a consensus price target of $7.25, suggesting a potential upside of 74.49%. Spectral AI has a consensus price target of $4.00, suggesting a potential upside of 137.39%. Given Spectral AI's higher possible upside, analysts plainly believe Spectral AI is more favorable than KORU Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

KORU Medical Systems has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, Spectral AI has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

In the previous week, Spectral AI had 2 more articles in the media than KORU Medical Systems. MarketBeat recorded 5 mentions for Spectral AI and 3 mentions for KORU Medical Systems. Spectral AI's average media sentiment score of 0.82 beat KORU Medical Systems' score of 0.62 indicating that Spectral AI is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KORU Medical Systems	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spectral AI	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

KORU Medical Systems has a net margin of -5.27% compared to Spectral AI's net margin of -85.58%. Spectral AI's return on equity of 0.00% beat KORU Medical Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KORU Medical Systems	-5.27%	-13.61%	-8.33%
Spectral AI	-85.58%	N/A	-72.97%

Summary

KORU Medical Systems beats Spectral AI on 9 of the 16 factors compared between the two stocks.

How does Spectral AI compare to Biosig Technologies?

Biosig Technologies (NASDAQ:STEX) and Spectral AI (NASDAQ:MDAI) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Biosig Technologies has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market. Comparatively, Spectral AI has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market.

In the previous week, Spectral AI had 3 more articles in the media than Biosig Technologies. MarketBeat recorded 5 mentions for Spectral AI and 2 mentions for Biosig Technologies. Biosig Technologies' average media sentiment score of 0.97 beat Spectral AI's score of 0.82 indicating that Biosig Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Biosig Technologies	Positive
Spectral AI	Positive

7.2% of Biosig Technologies shares are held by institutional investors. Comparatively, 67.1% of Spectral AI shares are held by institutional investors. 52.7% of Biosig Technologies shares are held by insiders. Comparatively, 13.7% of Spectral AI shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Spectral AI has higher revenue and earnings than Biosig Technologies. Spectral AI is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	3,785.99	-$462.77M	-$9.71	N/A
Spectral AI	$19.65M	2.73	-$7.57M	-$0.53	N/A

Biosig Technologies has a net margin of 0.00% compared to Spectral AI's net margin of -85.58%. Spectral AI's return on equity of 0.00% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
Spectral AI	-85.58%	N/A	-72.97%

Biosig Technologies currently has a consensus target price of $8.00, suggesting a potential upside of 860.38%. Spectral AI has a consensus target price of $4.00, suggesting a potential upside of 137.39%. Given Biosig Technologies' higher possible upside, equities analysts plainly believe Biosig Technologies is more favorable than Spectral AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Biosig Technologies and Spectral AI tied by winning 7 of the 14 factors compared between the two stocks.

Get Spectral AI News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDAI vs. The Competition

Export

Metric	Spectral AI	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$53.87M	$7.41B	$6.76B	$12.50B
Dividend Yield	N/A	1.32%	2.68%	8.00%
P/E Ratio	-3.19	49.94	26.93	24.41
Price / Sales	2.73	75.78	586.18	117.36
Price / Cash	N/A	26.85	29.22	49.36
Price / Book	-8.87	7.20	10.94	6.33
Net Income	-$7.57M	$162.30M	$3.58B	$330.66M
7 Day Performance	-3.16%	-1.61%	-2.10%	-0.66%
1 Month Performance	-7.42%	-0.48%	3.21%	-0.14%
1 Year Performance	-37.13%	3.46%	26.34%	20.16%

Spectral AI Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDAI Spectral AI	2.5865 of 5 stars	$1.69 +0.3%	$4.00 +137.4%	-41.3%	$53.87M	$19.65M	N/A	83
RXST RxSight	2.8648 of 5 stars	$5.62 +0.4%	$8.89 +58.2%	-36.8%	$231.82M	$134.48M	N/A	220	Analyst Upgrade
SMTI Sanara MedTech	2.4429 of 5 stars	$24.79 -1.5%	$34.00 +37.2%	-14.2%	$230.66M	$103.12M	N/A	60	News Coverage Positive News Gap Up
LUCD Lucid Diagnostics	4.1662 of 5 stars	$1.03 -4.6%	$4.19 +306.6%	-13.1%	$219.31M	$4.71M	N/A	70	Positive News
KRMD KORU Medical Systems	4.2804 of 5 stars	$4.59 -0.2%	$7.25 +58.0%	+21.6%	$211.29M	$41.13M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDAI) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spectral AI (MDAI) Competitors

MDAI vs. RXST, SMTI, LUCD, KRMD, and STEX

How does Spectral AI compare to RxSight?

Summary

How does Spectral AI compare to Sanara MedTech?

Summary

How does Spectral AI compare to Lucid Diagnostics?

Summary

How does Spectral AI compare to KORU Medical Systems?

Summary

How does Spectral AI compare to Biosig Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDAI vs. The Competition

Spectral AI Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spectral AI (MDAI) Competitors

MDAI vs. RXST, SMTI, LUCD, KRMD, and STEX

How does Spectral AI compare to RxSight?

Do analysts rate MDAI or RXST?

Is MDAI or RXST more profitable?

Which has more volatility and risk, MDAI or RXST?

Does the media refer more to MDAI or RXST?

Do insiders & institutionals have more ownership in MDAI or RXST?

Which has preferable valuation and earnings, MDAI or RXST?

Summary

How does Spectral AI compare to Sanara MedTech?

Do institutionals & insiders have more ownership in MDAI or SMTI?

Do analysts prefer MDAI or SMTI?

Is MDAI or SMTI more profitable?

Does the media prefer MDAI or SMTI?

Which has preferable valuation & earnings, MDAI or SMTI?

Which has more volatility and risk, MDAI or SMTI?

Summary

How does Spectral AI compare to Lucid Diagnostics?

Which has more risk and volatility, LUCD or MDAI?

Which has better valuation & earnings, LUCD or MDAI?

Does the media prefer LUCD or MDAI?

Do analysts prefer LUCD or MDAI?

Do institutionals and insiders hold more shares of LUCD or MDAI?

Is LUCD or MDAI more profitable?

Summary

How does Spectral AI compare to KORU Medical Systems?

Which has better valuation and earnings, KRMD or MDAI?

Do insiders & institutionals hold more shares of KRMD or MDAI?

Do analysts recommend KRMD or MDAI?

Which has more volatility & risk, KRMD or MDAI?

Does the media favor KRMD or MDAI?

Is KRMD or MDAI more profitable?

Summary

How does Spectral AI compare to Biosig Technologies?

Which has more volatility & risk, STEX or MDAI?

Does the media prefer STEX or MDAI?

Do insiders & institutionals hold more shares of STEX or MDAI?

Which has higher valuation and earnings, STEX or MDAI?

Is STEX or MDAI more profitable?

Do analysts prefer STEX or MDAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDAI vs. The Competition

Spectral AI Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools